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1. Introduction 
Two important targets from medical treatment are: pain control and suppression of disease 
progress. Most of the time, the effectiveness is temporary and lasted while these drugs have 
been used, which is expected from the nature of endometriosis disease .Of course, there are 
some debts about the usefulness of pain relief agents, because 30-50% of patients feel better 
with placebo administration. 
It must to keep in mind that those common administrated drugs  couldn’t help to restore the 
fertility potentials and in fact during their usage pregnancy cannot or should not be 
happened, regarding to inhibition of ovulation or teratogenic effects; of course by their 
administration with remission of disease (suppress the growth and activity of previous 
endometriotic implants) and reducing the chance of new peritoneal seeding, fertility may be 
preserved better; but at the end for achieving pregnancy other ways should be used.  
Medical therapeutic drugs divided in two categories: 
a. Non hormonal medical therapy. 
b. Hormonal medical therapy. 
Non hormonal therapeutic options, mainly work on inflammatory and immunologic aspect 
of endometriosis and hormonal attempts basically deprived endometriotic implants from 
their nutritive substance: estrogen.   
2. Non hormonal medical therapy 
2.1 Non-steroidal anti- inflammatory agents 
With attention to inflammatory nature of endometriosis, for decades non- steroidal anti- 
inflammatory agents (NSAIDs) such as naproxen and ibuprofen have been administrated 
for pain control, in endometriosis. These drugs have been reduced prostaglandins (PGs) 
production, the main stimulator factor in peritoneal nerves and decrease the nociceptor 
input messenger from the peritoneal endometriotic implants into central nervous system. 
Their gastrointestinal upsets and inhibition of ovulation (Duffy &Stouffer,2002) against low 
cost and easy availability, always puts NSAIDs in a challenging situation; rather than, new 
NSAIDs as a selective cyclooxygenase (COX)-2 inhibitors like celecoxib without any effect 
on PG pathway, could induce apoptosis in endometriotic implants (Seo etal,2010). However 
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the latest Cochrane review doesn’t show significant effective role of these drugs in patients 
with endometriosis (Davis etal, 2007).  
2.2 Cytokines inhibitors 
Research in this field is still in primary stages. In animal experiments, cytokines antagonist 
agents like recombinant human tumor necrotizing factor alpha (TNF-α) binding protein could 
inhibit the progress of endometriotic implants and formation of their adhesion (Barrier 
etal,2004;D’Hooghe etal,2006). Etanercept (ETA) as a TNF antagonist could decrease the 
volume of peritoneal fluid and proliferation of lesions in endometriotic rats (Zulfikaroglu 
etal,2011).  In a novel study, has been found that TNF could activate estrogen receptor α (ERα); 
therefore co-administration of  a pure ER antagonist with TNF inhibitor could be a more 
efficacious therapeutic method than usage of one agent, separately (Gori etal,2011). 
2.3 New anti inflammatores 
In cases with persistent non responsive symptom to NSAIDs, other inflammatores like 
leukotrienes could be inhibited (Abu etal, 2000). In one new study, leukotriene receptor 
antagonist has been shown to have a significant effect in reduction of stromal proliferation 
in endometriotic implants (Ihara etal, 2004). 
2.4 Immuno modulators 
Pentoxiphylline administration in human, like a leukotriene receptor antagonist, had 
promising results in patients with endometriosis. Although it is famous as a vasodilator agent 
and increase tissue oxygenation in some disease; but could change the immune cell function 
by inhibition of cytokine and TNF-α secretion. Although in a Cochran review in year 2009, 
there were not shown enough evidence to support  any differences in pregnancy rate in 
treated patients in comparison with placebo (Lu etal,2009); but in a new report, Vascular 
endothelial growth factor (VEGF)-C  suggested to be  an effective factor for significant 
reduction in endometriotic implants after Pentoxiphylline administration (Vlahos etal,2010). 
Also, other immuno modulators like etanercept (ETA) had promising reductive effect 
equally to letrozole in early investigation (Ceyhan etal ,2011). 
2.5 Alternative medicine 
In a 16 weeks prospective clinical trial, Chinese herbal medicine (CHM) decoctions have 
been disclosed hopeful reduction in patient’s symptoms especially with dysmenorrhea 
complaint rather than placebo (Flower etal, 2011).  According to Cochrane review, CHM 
have been shown equal results in comparison with gestrinone with lesser side effects; beside 
that, the combination of oral CMH administration with a CMH enema appear better clinical 
outcomes (Flower etal, 2009). 
As well, there are some published studies about the effectiveness of acupuncture in 
abdominal pain and significantly in dysmenorrhea relief (M.Chen etal ,2010 ; Rubi-Klein 
etal,2010). In another clinical trial, abdominal acupuncture causing decrease in CA125 level 
in endometriotic patients (Xiang etal, 2011).    
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3. Hormonal medical therapy 
3.1 Oral contraceptive pill (OCP) 
Oral combined contraceptive pills induce atrophy in peritoneal endometriotic implants by 
initial decidualization effect like a pseudo pregnancy situation; perhaps they could increase 
the apoptosis in endometriotic implants (Meresman etal , 2000).  OCPs are the most 
prescripted drugs in endometriosis, especially in minimal and mild stages of disease for 
pain control ; although there is a new report about the effectiveness of OCPs usage in 
patients with deep endometriotic nodules (advance stage) (Mabrouk etal,2011) ,which 
eliminate the effectiveness of OCPs administration  only in early stages of disease.  In 
addition, there is not any differences between various available formulations in pain relief 
potency and any kind of OCPs which had 30-35µg of ethinyl estradiol could be used and 
there is no necessity for high dose (HD) contraceptive administration (with 50 µg of ethinyl 
estradiol) (Davis etal,2007) . About the usage methods has been shown that, continues usage 
had better clinical results rather than cyclic administration (Harada etal,2008). In cases of 
sever atrophy of endometrium and break through bleeding, supplemental estrogen for 7-10 
days could be advised.     
3.2 Progestins 
Progestins at the first stage of administration induce decidualization in endometriotic 
tissues and at the second phase by proliferation inhibition makes atrophia. Also, progestins 
make depletion in estrogen receptors and inhibit their activation (Kirkland etal, 1992). 
Progestins could induce transformation of potent form of estrogens (estradiol) to weaker 
product (estrone) (Tseng etal, 1981) .In recent studies discover that there are two important 
catalyzer enzymes which metabolize progesterone in endometriotic implants. Aldo-Keto 
reductase 1C1 and 1C3 (AKR1C1 & AKR1C3) had significant up-regulation expression in 
ovarian endometriosis which interfere with inhibitory effects of human progesterone (Hevir 
etal, 2011). It found that exogenous progestins administration could inhibit their activity 
(Beranic etal, 2011).Various available progestins could be used: oral, parenteral, intrauterine 
device and implants. With higher dosage of administrated progestins, another effective role 
of them could be achieved: inhibition of matrix metalloproteinase (Osteen etal , 2003). Most 
of the time the clinical response to progestins are like the oral contraceptive pills (Schlaff 
etal,2006), without significant side effects except breakthrough bleeding which can be 
managed with short time, low dose estrogen administration. Also, the probably bone loss 
effect is reversible (Cundy etal,1996).The levonorgestrel releasing intrauterine device (LNG-
IUS) is a valuable therapeutic option especially for women with deep infiltrative 
endometriotic implants (Lochat etal,2005).About the pain relief efficacy of progestin 
subdermal implants (Implanon) evidences are limited than other therapeutic modalities 
(Yisa etal,2005). 
3.3 Gonadotropin-releasing hormone agonists 
Gonadotropin –releasing hormone (GnRH) agonists are synthetic drugs which are resistant 
to degeneration in body and are produced by some variation in amino acids consequent in 
natural GnRH agonists. Their resistance to degeneration makes the pituitary gland into 
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down regulation state and after suppression of FSH and LH production, menstruation and 
ovulation had been stopped and therefore, low estrogenic environment achieved which 
inhibits the proliferation in endometriotic implants. Beside initial flare effect, pseudo 
menopausal situation produce minor side effects like hot flashes, vaginal atrophia and 
dryness, headache and other vasomotor signs and symptoms (Dlugi etal,1990) which could 
be managed by add-back therapy, but after 6 or more continues cycles of drug 
administration, bone mineral density is going to be reduced sometimes in an irreversible 
manner (Taga etal,1996); but there is an interesting report about ten years usage of GnRH 
agonist with add-back therapy without any bone mineral loss (Bedaiwy etal,2006).  Unlike 
the progestins and danazole, GnRH agonists had not adverse effects on lipid profile (Burry 
etal,1989).Several kinds of injectable GnRH agonists and nasal spray form are available with 
equal efficacy (Prentice etal,2000). 
3.4 Gonadotropin-releasing hormone antagonists 
Regarding to initial flare effect of GnRH agonist administration and probably exacerbation 
effect on endometriosis and a delay between their administration and real hypo estrogenic 
state and their intolerable side effects in some patients, GnRH antagonists became an 
suitable  substitute for GnRH agonists. Weekly subcutaneous 3-mg cetrotide (GnRH 
antagonist) injection had been shown clinical efficacy without pseudo menopausal side 
effects (Finas etal, 2006; Kupker etal, 2002).There are some published advances in oral GnRH 
antagonist production: Elagolix (C.Chen et al, 2008). In a double blind study in 55 patients, 
weekly usage of this drug , results effective suppression of gonadal hormonal production 
(Struthers etal,2009), which could be a promising development in endometriosis treatments 
modalities instated of injectable options. 
3.5 Androgens 
Danazol is a derivation from testosterone which effect on endometriosis from several 
ways. Danazol inhibit some steroidogenic enzymes and elevate free testosterone and 
reduce estrogen level (Barbieri etal, 1981). Also, danazol inhibit mid cycle LH surge 
(Tamura etal, 1991) and PG F2α production in ovary (Kogo etal,1992),which both of them 
result chronic anovulation and decrease the chance of new peritoneal seeding.Danazol 
with 400-800 mg/daily recommended dosage regress the endometriotic implants (Telimaa 
etal,1987), but severe side effects prevent such dosage administration for an effective 
period (6 months) (Miller etal,1998).Oily skin, acne, hirsutism, irreversible voice deepness, 
variation in lipid profile, vaginal atrophia and hot flash limited it’s prescription (Hayashi 
etal,2001).  
3.6 Aromatase inhibitors 
In opposition to other hormonal therapeutic options which reduce ovarian estrogenic 
production, aromatase inhibitors act not only locally on endometriotic implants, but also on 
all of estrogenic producers: ovary, brain, adipose tissues (Attar&Bulun, 2006). Anastrazole 
1mg or letrozole 2.5mg daily could be effective in pain relief associated with endometriosis 
(Nothnick, 2011; Shippen&West, 2004). Because of stimulatory action of aromatase 
inhibitors in FSH secretion, in premenopausal women they could cause ovarian cysts; 
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therefore they administrate with GnRH agonist or OCPs or progestins. This method could 
reduce the concern about their disadvantage in prolong usage: bone loss (Ferrero etal  
,2009). 
3.7 Prolactin secretion inhibitors 
Suppression of cellular immunity and NK cell activity in endometriotic patients has been 
well known. Also, in stressful situations inhibition of NK cell had been found (Chrousos 
etal, 2000). Prolactin and cortisol levels in serum are stress indicators. Of course the 
mechanism of hyper prolactinemia in response to stress isn’t so clear, elevated level of 
serum prolactin had been found in endometriosis like other stressful conditions (Lima etal, 
2006, Wang etal, 2009). Interestingly the mean serum prolactin levels are higher in advance 
stages in endometriotic patients (Gregoriou etal ,1999). Quinagolide as a dopamine receptor 
2 agonist by reduction in VEGF receptor (a main factor for angiogenesis) could decrease the 
size of peritoneal lesions and in some cases could eradicate all of endometriotic implants 
(Gomez etal, 2011). From another aspect quinagolide, is a valuable option for hyper 
prolactinemia like other dopamine agonists (bromocriptine or caberguline) 
(Barlier&Jaquet,2006); therefore this drug could be effectively administrated in 
endometriosis. 
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